Table 1 Illumina MiSeq amplicon sequencing for rMP12-ΔNSs16/198 (Vero cells, Exp-1, p25)

From: Genetic stability of Rift Valley fever virus MP-12 vaccine during serial passages in culture cells

Segment

PCR fragmenta

Location

nt. mutation

aa. mutation

Variant reads

Total coverage

%

M

nt.705-1165

719

U to A

S to R

28992

267685

10.8

  

877

A to U

Q to L

202505

601576

33.7

  

1163

C to U

–

159382

910283

17.5

  

1165

A to G

K to R

344469

866107

39.8

 

nt.3369-3815

3412

C to U

T to I

10400

863570

1.2

  

3555

U to C

Y to H

39842

2246190

1.8

  

3564b

G to A

G to R

124721

2182917

5.7

  

3684

C to U

–

96600

2129301

4.5

  

3733

A to G

–

39842

2246190

1.3

L

nt.2850-3295

3240

C to A

–

47726

2514812

1.9

 

nt.3733-4170

3750b

A to G

I to M

438643

530118

82.7

  

3814

U to C

–

944868

995347

94.9

  

3816

A to C

–

944042

995263

94.9

  

4142

A to C

I to T

5485

416681

1.3

  1. The PCR fragments were amplified from viral RNA extracted from culture supernatants of rMP12-ΔNSs16/198 (Exp-1) at passage 25. The threshold of variant detection was set as 1%. nt., nucleotide; aa., amino acid
  2. a Nucleotide positions of PCR fragments in the antiviral-sense M- or L-segment. Primer regions are excluded
  3. b Reversion mutations to parental ZH548 strain
Back to article page